Skip to main content
Top
Published in: Osteoporosis International 2/2013

01-02-2013 | Original Article

Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis

Authors: R. B. Hopkins, J. E. Tarride, W. D. Leslie, C. Metge, L. M. Lix, S. Morin, G. Finlayson, M. Azimaee, E. Pullenayegum, R. Goeree, J. D. Adachi, A. Papaioannou, L. Thabane

Published in: Osteoporosis International | Issue 2/2013

Login to get access

Abstract

Summary

Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative magnitude to other chronic diseases such as stroke or heart disease. Prevalent fractures also have significant excess costs that are similar in relative magnitude to asthma/chronic obstructive pulmonary disease.

Introduction

Cost of illness studies for osteoporosis that only include incident fractures may ignore the long-term cost of prevalent fractures and primary preventive care. We estimated the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis relative to matched controls.

Methods

Men and women age 50+ were selected from administrative records in the province of Manitoba, Canada for the fiscal year 2007–2008. Three types of cases were identified: (1) patients with incident fractures in the current year (2007–2008), (2) patients with prevalent fractures in previous years (1995–2007), and (3) nonfracture osteoporosis patients identified by specific pharmacotherapy or low bone mineral density. Excess resource utilization and costs were estimated by subtracting control means from case means.

Results

Seventy-three percent of provincial population age 50+ (52 % of all men and 91 % of all women) were included (121,937 cases, 162,171 controls). There were 3,776 cases with incident fracture (1,273 men and 2,503 women), 43,406 cases with prevalent fractures (15,784 men and 27,622 women) and 74,755 nonfracture osteoporosis cases (7,705 men and 67,050 women). All incident fractures had significant excess costs. Incident hip fractures had the highest excess cost: men $44,963 (95 % CI: $38,498–51,428) and women $45,715 (95 % CI: $36,998–54,433). Prevalent fractures (other than miscellaneous or wrist fractures) also had significant excess costs. No significant excess costs existed for nonfracture osteoporosis.

Conclusion

Significant excess costs exist for patients with incident fractures and with prevalent hip, vertebral, humerus, multiple, and traumatic fractures. Ignoring prevalent fractures underestimate the true cost of osteoporosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA, Adachi JD, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Construction of a FRAX(R) model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 22:817–827PubMedCrossRef Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA, Adachi JD, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Construction of a FRAX(R) model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 22:817–827PubMedCrossRef
2.
go back to reference Statistics Canada (2010) Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual. Table 051–0001 Statistics Canada (2010) Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual. Table 051–0001
3.
go back to reference Becker DJ, Kilgore ML, Morrisey MA (2010) The societal burden of osteoporosis. Curr Rheumatol Rep 12:186–191PubMedCrossRef Becker DJ, Kilgore ML, Morrisey MA (2010) The societal burden of osteoporosis. Curr Rheumatol Rep 12:186–191PubMedCrossRef
4.
go back to reference Akobundu E, Ju J, Blatt L, Mullins CD (2006) Cost-of-illness studies: a review of current methods. PharmacoEconomics 24:869–890PubMedCrossRef Akobundu E, Ju J, Blatt L, Mullins CD (2006) Cost-of-illness studies: a review of current methods. PharmacoEconomics 24:869–890PubMedCrossRef
5.
go back to reference Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269–280PubMedCrossRef Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269–280PubMedCrossRef
6.
go back to reference Leslie WD, Metge CJ, Azimaee M, Lix LM, Finlayson GS, Morin SN, Caetano P (2011) Direct costs of fractures in Canada and trends 1996–2006: a population-based cost-of-illness analysis. J Bone Miner Res 26(10):2419–2429PubMedCrossRef Leslie WD, Metge CJ, Azimaee M, Lix LM, Finlayson GS, Morin SN, Caetano P (2011) Direct costs of fractures in Canada and trends 1996–2006: a population-based cost-of-illness analysis. J Bone Miner Res 26(10):2419–2429PubMedCrossRef
7.
go back to reference Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E (2001) Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 12:271–278PubMedCrossRef Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E (2001) Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 12:271–278PubMedCrossRef
8.
go back to reference Melton LJ III, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383–388PubMedCrossRef Melton LJ III, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383–388PubMedCrossRef
9.
go back to reference Orsini LS, Rousculp MD, Long SR, Wang S (2005) Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 16:359–371PubMedCrossRef Orsini LS, Rousculp MD, Long SR, Wang S (2005) Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 16:359–371PubMedCrossRef
10.
go back to reference Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET (2010) Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. PharmacoEconomics 28:395–409PubMedCrossRef Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET (2010) Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. PharmacoEconomics 28:395–409PubMedCrossRef
11.
go back to reference Rousculp MD, Long SR, Wang S, Schoenfeld MJ, Meadows ES (2007) Economic burden of osteoporosis-related fractures in Medicaid. Value Health 10:144–152PubMedCrossRef Rousculp MD, Long SR, Wang S, Schoenfeld MJ, Meadows ES (2007) Economic burden of osteoporosis-related fractures in Medicaid. Value Health 10:144–152PubMedCrossRef
12.
go back to reference Goeree R, O’Reilly D, Hopkins R, Blackhouse G, Tarride JE, Xie F, Lim M (2010) General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. Expert Rev Pharmacoecon Outcomes Res 10:379–384PubMedCrossRef Goeree R, O’Reilly D, Hopkins R, Blackhouse G, Tarride JE, Xie F, Lim M (2010) General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. Expert Rev Pharmacoecon Outcomes Res 10:379–384PubMedCrossRef
13.
go back to reference Knottnerus A, Tugwell P (2008) STROBE—a checklist to strengthen the reporting of observational studies in epidemiology. J Clin Epidemiol 61:323PubMedCrossRef Knottnerus A, Tugwell P (2008) STROBE—a checklist to strengthen the reporting of observational studies in epidemiology. J Clin Epidemiol 61:323PubMedCrossRef
14.
go back to reference Manitoba Centre for Health Policy (2010) University of Manitoba, Canada Manitoba Centre for Health Policy (2010) University of Manitoba, Canada
15.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC classification and DDD assignment (2010) Oslo, 2009 WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC classification and DDD assignment (2010) Oslo, 2009
16.
go back to reference Kozyrskyj AL, Mustard CA (1998) Validation of an electronic, population-based prescription database. Ann Pharmacother 32:1152–1157PubMedCrossRef Kozyrskyj AL, Mustard CA (1998) Validation of an electronic, population-based prescription database. Ann Pharmacother 32:1152–1157PubMedCrossRef
17.
go back to reference Poss JW, Hirdes JP, Fries BE, McKillop I, Chase M (2008) Validation of Resource Utilization Groups version III for Home Care (RUG-III/HC): evidence from a Canadian home care jurisdiction. Med Care 46:380–387PubMedCrossRef Poss JW, Hirdes JP, Fries BE, McKillop I, Chase M (2008) Validation of Resource Utilization Groups version III for Home Care (RUG-III/HC): evidence from a Canadian home care jurisdiction. Med Care 46:380–387PubMedCrossRef
18.
go back to reference Ontario Ministry of Health and Long Term Care (2010) Long-Term Care Home Financial Policy. Ontario Ministry of Health and Long Term Care Ontario Ministry of Health and Long Term Care (2010) Long-Term Care Home Financial Policy. Ontario Ministry of Health and Long Term Care
19.
go back to reference Canadian Institute for Health Information (2010) Canadian MIS Database—hospital financial performance indicators, 1999–2000 to 2008–2009 Canadian Institute for Health Information (2010) Canadian MIS Database—hospital financial performance indicators, 1999–2000 to 2008–2009
20.
go back to reference Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ (2006) A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59:342–353PubMedCrossRef Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ (2006) A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59:342–353PubMedCrossRef
21.
go back to reference Briggs AH, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, USA Briggs AH, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, USA
22.
go back to reference Goeree R, O’Reilly D, Hux J, Lim M, Hopkins R, Tarride J, Blackhouse G, Xie F (2009) Total and excess costs of diabetes and related complications in Ontario. Can J Diabetes 33:35–45 Goeree R, O’Reilly D, Hux J, Lim M, Hopkins R, Tarride J, Blackhouse G, Xie F (2009) Total and excess costs of diabetes and related complications in Ontario. Can J Diabetes 33:35–45
23.
go back to reference Finlayson G, Ekuma O, Yogendran M, Burland E, Forget E (2010) The additional cost of chronic disease in Manitoba. Manitoba Centre for Health Policy, Winnipeg Finlayson G, Ekuma O, Yogendran M, Burland E, Forget E (2010) The additional cost of chronic disease in Manitoba. Manitoba Centre for Health Policy, Winnipeg
24.
go back to reference Cochrane Handbook for Systematic Reviews of Interventions (2011) Version 5.1.0 Cochrane Handbook for Systematic Reviews of Interventions (2011) Version 5.1.0
25.
go back to reference StataCorp. Stata Statistical Software: Release 11 (2009) StataCorp. Stata Statistical Software: Release 11 (2009)
26.
go back to reference Briggs AH, Mooney CZ, Wonderling DE (1999) Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat Med 18:3245–3262PubMedCrossRef Briggs AH, Mooney CZ, Wonderling DE (1999) Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat Med 18:3245–3262PubMedCrossRef
27.
go back to reference Willan AR, O’Brien BJ (1996) Confidence intervals for cost-effectiveness ratios: an application of Fieller’s theorem. Health Econ 5:297–305PubMedCrossRef Willan AR, O’Brien BJ (1996) Confidence intervals for cost-effectiveness ratios: an application of Fieller’s theorem. Health Econ 5:297–305PubMedCrossRef
28.
go back to reference Thompson SG, Barber JA (2000) How should cost data in pragmatic randomised trials be analysed? BMJ 320:1197–2000PubMedCrossRef Thompson SG, Barber JA (2000) How should cost data in pragmatic randomised trials be analysed? BMJ 320:1197–2000PubMedCrossRef
Metadata
Title
Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis
Authors
R. B. Hopkins
J. E. Tarride
W. D. Leslie
C. Metge
L. M. Lix
S. Morin
G. Finlayson
M. Azimaee
E. Pullenayegum
R. Goeree
J. D. Adachi
A. Papaioannou
L. Thabane
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 2/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-1997-7

Other articles of this Issue 2/2013

Osteoporosis International 2/2013 Go to the issue